Amazing Results From ICT-107 Glioblastoma Clinical Trial

ICT-107 is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma and is showing an 80.2% overall survival at 2yrs and 55% overall survival at 3yrs, with 38% of patients disease free at 3yrs…compared to a 26.5% overall survival at 2yrs and  16% at 3yrs for standard treatment. I like this approach because ICT-107 targets multiple tumor associated antigens, unlike monoclonal antibodies that only target one antigen. Furthermore, the side effects were rash and fatigue!
ImmunoCellular Therapeutics Announces 55% Overall Survival at 3 yrs from Phase I Study in Glioblastoma.


Comments

  1. Is this treatment available in Ontario or anywhere in Canada?

Speak Your Mind

*